Ligand

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results

Retrieved on: 
Mittwoch, Mai 15, 2024
Molecular imaging, Mayo Clinic, Investment, PRRT, FDA, BMY, IND, EANM, Prostate, Ligand, Research, Antibody, PET, Bangladesh Technical Education Board, Stony Brook University, PSMA, Fortis Healthcare, Therapeutic index, Society, Neoplasm, Small business, CMC, Melanoma, Cohort, ATM, Bristol Myers Squibb, Business, CATX, Food, Disease, Safety, Cancer, Patient, Radiopharmaceutical, Adenocarcinoma, Nivolumab, Diagnosis, SNMMI, Therapy, Prostate cancer, LNTH, Nuclear medicine, Acquisition, NETS, Glomus tumor, MC1R, Pharmaceutical industry

SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced first quarter financial results for the period ended March 31, 2024.

Key Points: 
  • SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced first quarter financial results for the period ended March 31, 2024.
  • “I am proud of the progress we are making with our clinical-stage proprietary radiopharmaceuticals,” said Thijs Spoor, Perspective Therapeutics' CEO.
  • The Company was informed by the investigator that preliminary data readout is expected in the second half of 2024.
  • Updated results from Cohorts 1 and 2 of the Phase 1/2a study are expected in the second half of 2024.

Aphios Granted US Patent For siRNA Targeted Therapeutics for Treatment of HIV-1 and Other Diseases

Retrieved on: 
Mittwoch, Mai 15, 2024
AIDS, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, CD4, Rhesus macaque, Human, Disulfiram-like drug, HIV, Corporation, Macaque, Patent, Public, CXCR4, Superfluidity, Infection, Small RNA, Ligand, Cell, CCR5, HIV-1, RNA, Liposome, Therapy, Virus

11,981,174 for CCR5 and CD4 siRNA-targeted therapeutics for treatment of HIV-1 and other diseases.

Key Points: 
  • 11,981,174 for CCR5 and CD4 siRNA-targeted therapeutics for treatment of HIV-1 and other diseases.
  • More than 35 million people have died from AIDS, and 37 million people are living with HIV worldwide.
  • SuperFluids are used to nanoencapsulate siRNA in phospholipid liposomes and lipid nanoparticles (nanosomes) for the improved delivery of siRNA and other biologics to diseased cells.
  • Nanosomal formulation of siRNA and small molecules offers a potential avenue to improving the efficacy of siRNA constructs.

Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma

Retrieved on: 
Montag, Mai 13, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Lung, Patient, INT, TIGIT, Pembrolizumab, Merck & Co., CD112, CD155, Disease, Safety, Data analysis, Cancer, Interim, Melanoma, Ligand, Lung cancer, IIB, RFS, MRK, Data monitoring committee, IIC, DMC, Pharmaceutical industry

The trial is evaluating the investigational coformulation of vibostolimab, an anti-TIGIT antibody, and pembrolizumab (KEYTRUDA®), Merck’s anti-PD-1 therapy, compared to KEYTRUDA alone, as adjuvant treatment for patients with resected high-risk melanoma (Stage IIB-IV).

Key Points: 
  • The trial is evaluating the investigational coformulation of vibostolimab, an anti-TIGIT antibody, and pembrolizumab (KEYTRUDA®), Merck’s anti-PD-1 therapy, compared to KEYTRUDA alone, as adjuvant treatment for patients with resected high-risk melanoma (Stage IIB-IV).
  • At a pre-planned analysis, data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria.
  • Merck has an extensive clinical development program evaluating the safety and efficacy of the vibostolimab and pembrolizumab coformulation alone and in combination with other agents in over 3,000 patients.
  • Ongoing Phase 3 studies evaluating the vibostolimab and pembrolizumab coformulation in lung cancer, which are routinely monitored by external data monitoring committees, include KeyVibe-003 , KeyVibe-006 , KeyVibe-007 and KeyVibe-008 .

Avicenna Introduces Machine Learning-Enhanced Medicinal Chemistry Platform to Accelerate the Last Mile of Small Molecule Drug Discovery

Retrieved on: 
Mittwoch, Mai 8, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, FDA, Drug design, Hearing, Kaiser, Risk, Ligand, Fasudil, Machine learning, Liotta, Partnership, Virology, ROCK, DRS, Engineering, Mathematics, Algorithm, Therapy, Microsoft, Chemistry, Neurology, DSM-IV codes, Medicine, Failure, Biology, Drug development, Emory University, Drug discovery, Chronic kidney disease, Microsoft Research, Cheminformatics, Pharmaceutical industry

Avicenna Biosciences today introduced an extension to its machine learning (ML) technology platform to enhance medicinal chemistry and expedite clinical-stage drug discovery.

Key Points: 
  • Avicenna Biosciences today introduced an extension to its machine learning (ML) technology platform to enhance medicinal chemistry and expedite clinical-stage drug discovery.
  • “Avicenna is applying novel ML methods to navigate the unknowns in medicinal chemistry and design around them.
  • Our methods allow a drug design team to learn from years of failure and optimize against validated targets more efficiently.
  • For more information on Avicenna and its technology platform or to inquire about partnership opportunities, visit www.avicenna-bio.com .

DP Technology DevDay 2024 Showcases Large Science Models and Announces Open Science Initiative

Retrieved on: 
Montag, April 29, 2024
Cloud, TDC, Table, Ligand, ICLR, RMSD, CATL, Computational chemistry, DFT, RNA, Research, PDF, Artificial intelligence, DP, Intelligence, Information technology, Cloud computing, Drug discovery, BioNTech, DPA, Messenger, ADMET, Drug development, Behavior, Algorithm, Westlake University, Fine chemical

As an AI for Science pioneer, DP Technology is continually collaborating with partners to explore the transformative impact AI can bring to science.

Key Points: 
  • As an AI for Science pioneer, DP Technology is continually collaborating with partners to explore the transformative impact AI can bring to science.
  • Inspired by recent advancements of large language models, DP aspires to develop a similar foundational model for the atomic domain.
  • Industrial Software for Drug Discovery, Battery Development and beyond
    Advancing AI for Science, DP Technology has developed a suite of industry applications based on its large science models and advanced algorithms.
  • Sun Weijie, founder and CEO of DP Technology, stated, "The launch of large science models is our firm commitment to advancing scientific and industrial innovation.

Avilar Therapeutics to Present Preclinical Data for MTAC (M6PR Targeting Chimera) Extracellular Protein Degrader Platform at the American Association of Immunologists Annual Meeting

Retrieved on: 
Mittwoch, Mai 1, 2024
Biotechnology, Pharmaceutical, Health, MTAC, M6P, ATAC, Protein, Hepatocyte, Ligand, Publication, Poster, Doctor of Philosophy, Journal, Chimera, ATACS, Therapy, Asialoglycoprotein receptor, Atomic mass, Fine chemical

Avilar Therapeutics , a biopharmaceutical company focused on extracellular protein degradation, today announced it will present preclinical proof-of-concept data for the company’s MTAC (M6PR Targeting Chimera) protein degrader platform at IMMUNOLOGY™ 2024, the American Association of Immunologists annual meeting taking place May 3-7 in Chicago, Illinois.

Key Points: 
  • Avilar Therapeutics , a biopharmaceutical company focused on extracellular protein degradation, today announced it will present preclinical proof-of-concept data for the company’s MTAC (M6PR Targeting Chimera) protein degrader platform at IMMUNOLOGY™ 2024, the American Association of Immunologists annual meeting taking place May 3-7 in Chicago, Illinois.
  • MTACs are novel bifunctional molecules containing a proprietary Avilar ligand to the mannose 6‑phosphate receptor (M6PR) conjugated to a second ligand that binds to a protein of interest for degradation.
  • MTACs represent an expansion of Avilar’s capabilities for extracellular protein degradation, building on the company’s ATAC (ASGPR Targeting Chimera) platform, which utilizes the asialoglycoprotein receptor (ASGPR) for degradation of proteins in the hepatocyte endolysosome.
  • Avilar scientists invented novel high affinity ligands to both ASGPR and M6PR, and these ligands form the chemistry backbone for ATACs and MTACs, respectively.

OPDIVO (Nivolumab) Drug Pipeline Research Report 2024: The First-in-human Immunoglobulin G4 (IgG4) PD-1 Immune Checkpoint Inhibitor Antibody - Market Size, Forecast, and Emerging Insights 2019-2032 - ResearchAndMarkets.com

Retrieved on: 
Donnerstag, April 18, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, PD-L2, SWOT, Ligand, EU4, Trial of the century, PD-1, Fibroadenoma, PD-L1, Immunoglobulin G, Patient, Neoplasm, Clinical trial, Ovarian cancer, Birth control

This report provides comprehensive insights about OPDIVO for ovarian cancer in the six major markets.

Key Points: 
  • This report provides comprehensive insights about OPDIVO for ovarian cancer in the six major markets.
  • The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities.
  • OPDIVO (also known as Nivolumab) is the first-in-human immunoglobulin G4 (IgG4) PD-1 immune checkpoint inhibitor antibody that disrupts the interaction of the PD-1 receptor with its ligands PD-L1 and PD-L2, thereby inhibiting the cellular immune response.
  • What are the other emerging products available and how are these giving competition to OPDIVO for ovarian cancer?

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

Retrieved on: 
Montag, April 8, 2024
B cell, Ligand, Patient, CHRS, Tumor microenvironment, LILRB2, Cancer, Macrophage, PD-1, Neonatal Fc receptor, IND, Phenotype, Neoplasm, Poster, ILT4, Vaccine

REDWOOD CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today presented preclinical data for its immuno-oncology pipeline candidate, CHS-1000, a novel ILT4 monoclonal antibody, at the 2024 AACR Annual Meeting being held in San Diego, California. Data presented show CHS-1000 is a potent monoclonal antibody that binds selectively to human ILT4 (also known as LILRB2) with high affinity, efficiently blocking interaction with its ligands and reversing immunosuppressive functions, leading to activation of human dendritic cells and T cells and promoting polarization of macrophages to an inflammatory M1 phenotype.

Key Points: 
  • “Myeloid cell-mediated immunosuppression in the tumor microenvironment is a major contributor to tumor immune invasion and PD-1 resistance.
  • The data presented in this poster demonstrate the potential for CHS-1000 to reverse myeloid suppression and activate an inflammatory immune response.
  • “CHS-1000 is our first internally discovered development candidate, and we are excited to be filing the IND this quarter.
  • ILT4 and CD163, a marker of suppressive (M2) macrophages, are highly expressed in a broad range of solid tumors.

Linkage of Cancer and Lupus in Gliomas Patients

Retrieved on: 
Montag, März 25, 2024
CD86, OS, TME, Gene, Transforming growth factor beta, CD68, Survival, LGG, Ligand, TGFB2, CD276, IDH, STAT1, Inflammation, Central nervous system, Patient, RNA, Tumor microenvironment, Cancer, Messenger, Macrophage, SLE, Expression, TAM, Treatment, Neoplasm, IRF5, Therapy, TGF, IRF1, TGFB, OTCQB, Demethylation, Vaccine

Dr. Vuong Trieu, CEO and Chairman of Oncotelic, stated, ”Our R&D team has discovered crosstalk between the TGF-β and IFN signaling pathways, linking gliomas and Systemic Lupus Erythematosus (SLE).

Key Points: 
  • Dr. Vuong Trieu, CEO and Chairman of Oncotelic, stated, ”Our R&D team has discovered crosstalk between the TGF-β and IFN signaling pathways, linking gliomas and Systemic Lupus Erythematosus (SLE).
  • Understanding the role of IRF5 in both SLE and cancer opens an avenue for targeting IRF5 or its downstream pathways.
  • LGG patients expressing high levels of TGFB2 and IFNGR2 are over-represented in IDH wild-type tumor samples, suggesting that TGFB2 and IFNGR2 mRNA can be therapeutically targeted in these high-risk patients.
  • Therefore, to improve OS in LGG patients, combination therapies must target TGFB2 and IFN-γ activation (via IRF5 inhibition) or immune therapies targeted against CD276/B7-H3

Innovations in Small Molecule Drug Delivery and Formulation, 2024 Research Report - Collaborating with CDMOs to Intensify R&D Activities - ResearchAndMarkets.com

Retrieved on: 
Donnerstag, April 4, 2024
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, Molecule, Nanocarriers, Exosome, Toxicity, Solubility, Cancer, Ligand, Generic drug

The "Innovations in Small Molecule Drug Delivery and Formulation" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Innovations in Small Molecule Drug Delivery and Formulation" report has been added to ResearchAndMarkets.com's offering.
  • Small molecules, which are the leading drug class across indications, face several issues that threaten their drug delivery efficacy.
  • While the small molecule drug development pipeline remains a leading therapeutic class, it is essential to intensify R&D to improve drug delivery approaches.
  • This analysis of the latest advances in small molecule drug delivery covers developments in organic, inorganic, and carrier-free small molecule drug delivery systems (DDSs) as well as developments in formulations for improved patient adherence and targeted small molecule delivery.